Immuneering Corp — Director's Dealing 2025

Mar 24, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-03-21

Reporting Person: Matushansky Igor (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-21	Stock Option	$1.80	A	118000	Acquired	2035-03-21	Class A Common Stock (118000)	Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the underlying shares on March 17, 2026 and then in equal monthly installments over the subsequent three years, subject to the reporting person's continued employment through each applicable vesting date.